154 related articles for article (PubMed ID: 37749027)
1. [Biologics in severe childhood asthma].
Amat F
Rev Mal Respir; 2023 Oct; 40(8):675-683. PubMed ID: 37749027
[TBL] [Abstract][Full Text] [Related]
2. Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis.
Nopsopon T; Lassiter G; Chen ML; Alexander GC; Keet C; Hong H; Akenroye A
J Allergy Clin Immunol; 2023 Mar; 151(3):747-755. PubMed ID: 36538979
[TBL] [Abstract][Full Text] [Related]
3. New perspectives of childhood asthma treatment with biologics.
Just J; Deschildre A; Lejeune S; Amat F
Pediatr Allergy Immunol; 2019 Mar; 30(2):159-171. PubMed ID: 30444939
[TBL] [Abstract][Full Text] [Related]
4. Treatment Resistance in Severe Asthma Patients With a Combination of High Fraction of Exhaled Nitric Oxide and Low Blood Eosinophil Counts.
Hoshino Y; Soma T; Uchida Y; Shiko Y; Nakagome K; Nagata M
Front Pharmacol; 2022; 13():836635. PubMed ID: 35517829
[No Abstract] [Full Text] [Related]
5. Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison.
Menzies-Gow A; Steenkamp J; Singh S; Erhardt W; Rowell J; Rane P; Martin N; Ackert JL; Quinton A
J Med Econ; 2022; 25(1):679-690. PubMed ID: 35570578
[TBL] [Abstract][Full Text] [Related]
6. Biologics in the treatment of asthma in children and adolescents.
Bacharier LB; Jackson DJ
J Allergy Clin Immunol; 2023 Mar; 151(3):581-589. PubMed ID: 36702649
[TBL] [Abstract][Full Text] [Related]
7. Comparative Efficacy and Safety of Tezepelumab and Other Biologics in Patients with Inadequately Controlled Asthma According to Thresholds of Type 2 Inflammatory Biomarkers: A Systematic Review and Network Meta-Analysis.
Ando K; Fukuda Y; Tanaka A; Sagara H
Cells; 2022 Feb; 11(5):. PubMed ID: 35269440
[TBL] [Abstract][Full Text] [Related]
8. Precision care in the treatment of pediatric asthma.
Mahmood L; Keskin S; Jefferson AA
Curr Opin Pediatr; 2024 Jun; 36(3):304-309. PubMed ID: 38411592
[TBL] [Abstract][Full Text] [Related]
9. [THE OVERLAPPING ELIGIBILITY FOR BIOLOGICS IN PATIENTS WITH SEVERE ASTHMA AND PHENOTYPES].
Ito A; Miyoshi S; Toyota H; Suzuki Y; Uehara Y; Hattori S; Takeshita Y; Sakasegawa H; Kuramochi M; Kobayashi K; Sugimoto N; Nagase H
Arerugi; 2022; 71(3):210-220. PubMed ID: 35569943
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of tezepelumab against uncontrolled severe non-type 2 asthma refractory to bronchial thermoplasty, benralizumab, dupilumab and mepolizumab.
Kai Y; Suzuki K; Kataoka R; Sato I; Tamaki S; Muro S
Respirol Case Rep; 2024 Mar; 12(3):e01311. PubMed ID: 38420113
[TBL] [Abstract][Full Text] [Related]
11. Biological treatments in childhood asthma.
Nieto-García A; Nieto-Cid M; Mazón-Ramos Á
Curr Opin Allergy Clin Immunol; 2024 Jun; 24(3):114-121. PubMed ID: 38567842
[TBL] [Abstract][Full Text] [Related]
12. Dual biologics for severe asthma and atopic dermatitis: Synopsis of two cases and literature review.
Matsumoto T; Sakurai Y; Tashima N; Matoba T; Kaneko A; Fujiki T; Kusakabe Y; Nakayama E; Tanaka A; Tashima M; Yamamoto N; Aihara K
Respirol Case Rep; 2024 Jan; 12(1):e01266. PubMed ID: 38074921
[TBL] [Abstract][Full Text] [Related]
13. Developments in the Management of Severe Asthma in Children and Adolescents: Focus on Dupilumab and Tezepelumab.
van Dijk YE; Rutjes NW; Golebski K; Şahin H; Hashimoto S; Maitland-van der Zee AH; Vijverberg SJH
Paediatr Drugs; 2023 Nov; 25(6):677-693. PubMed ID: 37658954
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
Agache I; Beltran J; Akdis C; Akdis M; Canelo-Aybar C; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Hernández-Martín I; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Posso M; Rocha C; Quirce S; Sastre J; Shamji M; Song Y; Steiner C; Schwarze J; Alonso-Coello P; Palomares O; Jutel M
Allergy; 2020 May; 75(5):1023-1042. PubMed ID: 32034960
[TBL] [Abstract][Full Text] [Related]
15. Anaphylaxis to three humanized antibodies for severe asthma: a case study.
Jingo K; Harada N; Nishioki T; Torasawa M; Yamada T; Asao T; Takagi H; Takeshige T; Ito J; Takahashi K
Allergy Asthma Clin Immunol; 2020; 16():46. PubMed ID: 32536947
[TBL] [Abstract][Full Text] [Related]
16. Differences in asthma-related outcomes by anti-IL-5 biologics, omalizumab, and dupilumab based on blood eosinophil counts.
Kimura Y; Suzukawa M; Inoue N; Imai S; Horiguchi H; Akazawa M; Matsui H
Asian Pac J Allergy Immunol; 2024 Jan; ():. PubMed ID: 38183647
[TBL] [Abstract][Full Text] [Related]
17. Molecular Targets for Biological Therapies of Severe Asthma: Focus on Benralizumab and Tezepelumab.
Cheng SL
Life (Basel); 2021 Jul; 11(8):. PubMed ID: 34440488
[TBL] [Abstract][Full Text] [Related]
18. Biologics for severe asthma: The real-world evidence, effectiveness of switching, and prediction factors for the efficacy.
Nagase H; Suzukawa M; Oishi K; Matsunaga K
Allergol Int; 2023 Jan; 72(1):11-23. PubMed ID: 36543689
[TBL] [Abstract][Full Text] [Related]
19. Severe Asthma and Biological Therapies: Now and the Future.
Sardon-Prado O; Diaz-Garcia C; Corcuera-Elosegui P; Korta-Murua J; Valverde-Molina J; Sanchez-Solis M
J Clin Med; 2023 Sep; 12(18):. PubMed ID: 37762787
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of Switching Biologics for Severe Asthma Patients in Japan: A Single-Center Retrospective Study.
Numata T; Araya J; Miyagawa H; Okuda K; Fujita Y; Utsumi H; Takekoshi D; Hashimoto M; Minagawa S; Ishikawa T; Hara H; Kuwano K
J Asthma Allergy; 2021; 14():609-618. PubMed ID: 34113131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
